Open AccessLGG-26. TYPE II BRAF INHIBITOR TAK-580 SHOWS PROMISE FOR UPCOMING CLINAL TRIAL AS EVIDENCED BY SINGLE PATIENT IND STUDY
Author(s) -
Karen Wright,
Mary Ann Zimmerman,
Elizabeth Fine,
Tristan Aspri,
Mark W. Kieran,
Susan Chi
Publication year - 2018
Publication title -
neuro-oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.005
H-Index - 125
eISSN - 1523-5866
pISSN - 1522-8517
DOI - 10.1093/neuonc/noy059.367
Subject(s) - medicine , rash , pharmacodynamics , in vivo , dosing , pharmacokinetics , adverse effect , pharmacology , oncology , cancer research , biology , genetics
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom